{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:52:11Z","timestamp":1790254331739,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T00:00:00Z","timestamp":1528329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI101990"],"award-info":[{"award-number":["U01 AI101990"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["7\/01\/2012-6\/30-2017"],"award-info":[{"award-number":["7\/01\/2012-6\/30-2017"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Digestive Disease Institute at Virginia Mason Medical Center","award":["1\/01\/2015-12\/31\/2015, J.D.L., PI"],"award-info":[{"award-number":["1\/01\/2015-12\/31\/2015, J.D.L., PI"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clim.2018.05.006","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T12:37:13Z","timestamp":1527338233000},"page":"24-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Circulating integrin alpha4\/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype"],"prefix":"10.1016","volume":"193","author":[{"given":"James D.","family":"Lord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-1240","authenticated-orcid":false,"given":"S. Alice","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Shows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerill","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Schwedhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane H.","family":"Buckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clim.2018.05.006_bb0005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00415-004-0332-4","article-title":"Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis","volume":"251","author":"Dalton","year":"2004","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.clim.2018.05.006_bb0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.clim.2018.05.006_bb0015","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1191\/1352458505ms1205oa","article-title":"Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis","volume":"11","author":"O'Connor","year":"2005","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.clim.2018.05.006_bb0020","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1212\/01.WNL.0000128136.79044.D6","article-title":"Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects","volume":"62","author":"O'Connor","year":"2004","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.clim.2018.05.006_bb0025","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.clim.2018.05.006_bb0030","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.53.3.466","article-title":"The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group","volume":"53","author":"Tubridy","year":"1999","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.clim.2018.05.006_bb0035","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.clim.2018.05.006_bb0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.clim.2018.05.006_bb0045","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ibd.21896","article-title":"Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study","volume":"18","author":"Parikh","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"issue":"8","key":"10.1016\/j.clim.2018.05.006_bb0050","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.clim.2018.05.006_bb0055","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.clim.2018.05.006_bb0060","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.clim.2018.05.006_bb0065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn's disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.clim.2018.05.006_bb0070","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/gast.2001.26260","article-title":"A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease","volume":"121","author":"Gordon","year":"2001","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clim.2018.05.006_bb0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(93)90305-A","article-title":"Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1","volume":"74","author":"Berlin","year":"1993","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.clim.2018.05.006_bb0080","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4049\/jimmunol.153.2.517","article-title":"Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes","volume":"153","author":"Erle","year":"1994","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2018.05.006_bb0085","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/gut.45.6.856","article-title":"Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7\/MAdCAM-1 and OX40\/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease","volume":"45","author":"Souza","year":"1999","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.clim.2018.05.006_bb0090","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2016","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.clim.2018.05.006_bb0095","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY Consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.clim.2018.05.006_bb0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/gutjnl-2016-312293","article-title":"Effect of vedolizumab (anti-alpha4beta7-integrin) therapy on histological healing and mucosal gene expression in patients with UC","volume":"67","author":"Arijs","year":"2016","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.clim.2018.05.006_bb0105","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.clim.2018.05.006_bb0110","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1146\/annurev-immunol-032414-112056","article-title":"Heterogeneity of human CD4(+) T cells against microbes","volume":"34","author":"Sallusto","year":"2016","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.clim.2018.05.006_bb0115","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.4049\/jimmunol.177.7.4488","article-title":"The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors","volume":"177","author":"Hirahara","year":"2006","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.clim.2018.05.006_bb0120","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#","article-title":"CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease","volume":"30","author":"Cosmi","year":"2000","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.clim.2018.05.006_bb0125","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.4049\/jimmunol.0904028","article-title":"Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells","volume":"184","author":"Thornton","year":"2010","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2018.05.006_bb0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/imr.12160","article-title":"tTregs, pTregs, and iTregs: similarities and differences","volume":"259","author":"Shevach","year":"2014","journal-title":"Immunol. Rev."},{"issue":"8","key":"10.1016\/j.clim.2018.05.006_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136485","article-title":"Human blood and mucosal regulatory T cells express activation markers and inhibitory receptors in inflammatory bowel disease","volume":"10","author":"Lord","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clim.2018.05.006_bb0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MIB.0000000000000242","article-title":"T-cell receptor sequencing reveals the clonal diversity and overlap of colonic effector and FOXP3+ T cells in ulcerative colitis","volume":"21","author":"Lord","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"issue":"6139","key":"10.1016\/j.clim.2018.05.006_bb0145","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1126\/science.1237013","article-title":"GPR15-mediated homing controls immune homeostasis in the large intestine mucosa","volume":"340","author":"Kim","year":"2013","journal-title":"Science"},{"issue":"6754","key":"10.1016\/j.clim.2018.05.006_bb0150","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.clim.2018.05.006_bb0155","first-page":"573","article-title":"Memory B cells and CD27","volume":"15","author":"Agematsu","year":"2000","journal-title":"Histol. Histopathol."},{"issue":"6","key":"10.1016\/j.clim.2018.05.006_bb0160","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2018.05.006_bb0165","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-018-4924-8","article-title":"Identification of candidate biomarkers associated with response to vedolizumab in inflammatory bowel disease","author":"Boden","year":"2018","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.clim.2018.05.006_bb0170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.187.1.129","article-title":"Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s","volume":"187","author":"Bonecchi","year":"1998","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.clim.2018.05.006_bb0175","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1084\/jem.20080397","article-title":"Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor","volume":"205","author":"Cosmi","year":"2008","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.clim.2018.05.006_bb0180","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4049\/jimmunol.173.1.68","article-title":"T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1\/Th2 effector cells that provide help for B cells","volume":"173","author":"Chtanova","year":"2004","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2018.05.006_bb0185","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s004410100417","article-title":"Function and interactions of integrins","volume":"305","author":"van der Flier","year":"2001","journal-title":"Cell Tissue Res."},{"issue":"6","key":"10.1016\/j.clim.2018.05.006_bb0190","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.clim.2018.05.006_bb0195","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.immuni.2012.09.020","article-title":"Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets","volume":"38","author":"Sathaliyawala","year":"2013","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.clim.2018.05.006_bb0200","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1097\/MIB.0000000000000203","article-title":"Naive T cells in the gut of newly diagnosed, untreated adult patients with inflammatory bowel disease","volume":"20","author":"Horjus Talabur Horje","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.clim.2018.05.006_bb0205","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ni.3079","article-title":"Role and species-specific expression of colon T cell homing receptor GPR15 in colitis","volume":"16","author":"Nguyen","year":"2015","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2018.05.006_bb0210","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/mi.2014.22","article-title":"T cell-associated alpha4beta7 but not alpha4beta1 integrin is required for the induction and perpetuation of chronic colitis","volume":"7","author":"Kurmaeva","year":"2014","journal-title":"Mucosal Immunol."},{"issue":"2","key":"10.1016\/j.clim.2018.05.006_bb0215","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1586\/eci.11.96","article-title":"Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease","volume":"8","author":"Raza","year":"2012","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2018.05.006_bb0220","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1398-9995.1992.tb00662.x","article-title":"Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy","volume":"47","author":"Del Prete","year":"1992","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.clim.2018.05.006_bb0225","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","article-title":"T follicular helper cell differentiation, function, and roles in disease","volume":"41","author":"Crotty","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2018.05.006_bb0230","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-065X.1995.tb00091.x","article-title":"Common cytokine receptor gamma chain (gamma c)-dependent cytokines: understanding in vivo functions by gene targeting","volume":"148","author":"Di Santo","year":"1995","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.clim.2018.05.006_bb0235","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0092-8674(93)80067-O","article-title":"Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene","volume":"75","author":"Sadlack","year":"1993","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.clim.2018.05.006_bb0240","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/1074-7613(95)90180-9","article-title":"Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment","volume":"3","author":"Willerford","year":"1995","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.clim.2018.05.006_bb0245","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1073\/pnas.87.7.2433","article-title":"The scurfy mouse mutant has previously unrecognized hematological abnormalities and resembles Wiskott-Aldrich syndrome","volume":"87","author":"Lyon","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.clim.2018.05.006_bb0250","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.clim.2018.05.006_bb0255","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/83784","article-title":"Disruption of a new forkhead\/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse","volume":"27","author":"Brunkow","year":"2001","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.clim.2018.05.006_bb0260","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI11966","article-title":"Escape from tolerance in the human X-linked autoimmunity-allergic disregulation syndrome and the Scurfy mouse","volume":"107","author":"Patel","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.clim.2018.05.006_bb0265","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/83707","article-title":"X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy","volume":"27","author":"Wildin","year":"2001","journal-title":"Nat. Genet."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618300652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618300652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T16:56:37Z","timestamp":1693673797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661618300652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":53,"alternative-id":["S1521661618300652"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2018.05.006","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating integrin alpha4\/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2018.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}